Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 106

Similar articles for PubMed (Select 23740994)

1.

Lack of prophylactic efficacy of oral maraviroc in macaques despite high drug concentrations in rectal tissues.

Massud I, Aung W, Martin A, Bachman S, Mitchell J, Aubert R, Solomon Tsegaye T, Kersh E, Pau CP, Heneine W, García-Lerma JG.

J Virol. 2013 Aug;87(16):8952-61. doi: 10.1128/JVI.01204-13. Epub 2013 Jun 5.

2.

Prevention of vaginal SHIV transmission in macaques by a coitally-dependent Truvada regimen.

Radzio J, Aung W, Holder A, Martin A, Sweeney E, Mitchell J, Bachman S, Pau CP, Heneine W, García-Lerma JG.

PLoS One. 2012;7(12):e50632. doi: 10.1371/journal.pone.0050632. Epub 2012 Dec 4.

3.

Pharmacokinetics and efficacy of a vaginally administered maraviroc gel in rhesus macaques.

Malcolm RK, Forbes CJ, Geer L, Veazey RS, Goldman L, Klasse PJ, Moore JP.

J Antimicrob Chemother. 2013 Mar;68(3):678-83. doi: 10.1093/jac/dks422. Epub 2012 Oct 30.

4.

Protection of rhesus macaques from vaginal infection by vaginally delivered maraviroc, an inhibitor of HIV-1 entry via the CCR5 co-receptor.

Veazey RS, Ketas TJ, Dufour J, Moroney-Rasmussen T, Green LC, Klasse PJ, Moore JP.

J Infect Dis. 2010 Sep 1;202(5):739-44. doi: 10.1086/655661.

5.

Sustained release of the CCR5 inhibitors CMPD167 and maraviroc from vaginal rings in rhesus macaques.

Malcolm RK, Veazey RS, Geer L, Lowry D, Fetherston SM, Murphy DJ, Boyd P, Major I, Shattock RJ, Klasse PJ, Doyle LA, Rasmussen KK, Goldman L, Ketas TJ, Moore JP.

Antimicrob Agents Chemother. 2012 May;56(5):2251-8. doi: 10.1128/AAC.05810-11. Epub 2012 Feb 13.

6.

Prevention of SIV rectal transmission and priming of T cell responses in macaques after local pre-exposure application of tenofovir gel.

Cranage M, Sharpe S, Herrera C, Cope A, Dennis M, Berry N, Ham C, Heeney J, Rezk N, Kashuba A, Anton P, McGowan I, Shattock R.

PLoS Med. 2008 Aug 5;5(8):e157; discussion e157. doi: 10.1371/journal.pmed.0050157.

7.

Natural substrate concentrations can modulate the prophylactic efficacy of nucleotide HIV reverse transcriptase inhibitors.

García-Lerma JG, Aung W, Cong ME, Zheng Q, Youngpairoj AS, Mitchell J, Holder A, Martin A, Kuklenyik S, Luo W, Lin CY, Hanson DL, Kersh E, Pau CP, Ray AS, Rooney JF, Lee WA, Heneine W.

J Virol. 2011 Jul;85(13):6610-7. doi: 10.1128/JVI.00311-11. Epub 2011 Apr 27.

8.

HIV pre-exposure prophylaxis: mucosal tissue drug distribution of RT inhibitor Tenofovir and entry inhibitor Maraviroc in a humanized mouse model.

Veselinovic M, Yang KH, LeCureux J, Sykes C, Remling-Mulder L, Kashuba AD, Akkina R.

Virology. 2014 Sep;464-465:253-63. doi: 10.1016/j.virol.2014.07.008. Epub 2014 Aug 7.

PMID:
25105490
9.

Maternal-fetal pharmacokinetics and dynamics of a single intrapartum dose of maraviroc in rhesus macaques.

Winters MA, Van Rompay KK, Kashuba AD, Shulman NS, Holodniy M.

Antimicrob Agents Chemother. 2010 Oct;54(10):4059-63. doi: 10.1128/AAC.00747-10. Epub 2010 Aug 9.

10.

Prevention of rectal SHIV transmission in macaques by daily or intermittent prophylaxis with emtricitabine and tenofovir.

García-Lerma JG, Otten RA, Qari SH, Jackson E, Cong ME, Masciotra S, Luo W, Kim C, Adams DR, Monsour M, Lipscomb J, Johnson JA, Delinsky D, Schinazi RF, Janssen R, Folks TM, Heneine W.

PLoS Med. 2008 Feb;5(2):e28. doi: 10.1371/journal.pmed.0050028.

11.

T cell chemo-vaccination effects after repeated mucosal SHIV exposures and oral pre-exposure prophylaxis.

Kersh EN, Adams DR, Youngpairoj AS, Luo W, Zheng Q, Cong ME, Aung W, Mitchell J, Otten R, Hendry RM, Heneine W, McNicholl J, Garcia-Lerma JG.

PLoS One. 2011 Apr 26;6(4):e19295. doi: 10.1371/journal.pone.0019295.

12.

SHIV-162P3 infection of rhesus macaques given maraviroc gel vaginally does not involve resistant viruses.

Tsibris AM, Pal U, Schure AL, Veazey RS, Kunstman KJ, Henrich TJ, Klasse PJ, Wolinsky SM, Kuritzkes DR, Moore JP.

PLoS One. 2011;6(12):e28047. doi: 10.1371/journal.pone.0028047. Epub 2011 Dec 2.

13.

Short communication: no evidence of occult SHIV infection as demonstrated by CD8+ cell depletion after chemoprophylaxis-induced protection from mucosal infection in rhesus macaques.

Kersh EN, Luo W, Adams DR, Mitchell J, Garcia-Lerma JG, Heneine W, Folks TM, Butera S, Otten RA.

AIDS Res Hum Retroviruses. 2008 Apr;24(4):543-6. doi: 10.1089/aid.2007.0222.

PMID:
18370590
14.

A common mechanism of clinical HIV-1 resistance to the CCR5 antagonist maraviroc despite divergent resistance levels and lack of common gp120 resistance mutations.

Roche M, Salimi H, Duncan R, Wilkinson BL, Chikere K, Moore MS, Webb NE, Zappi H, Sterjovski J, Flynn JK, Ellett A, Gray LR, Lee B, Jubb B, Westby M, Ramsland PA, Lewin SR, Payne RJ, Churchill MJ, Gorry PR.

Retrovirology. 2013 Apr 20;10:43. doi: 10.1186/1742-4690-10-43.

15.

CNS effects of a CCR5 inhibitor in HIV-infected subjects: a pharmacokinetic and cerebral metabolite study.

Garvey L, Nelson M, Latch N, Erlwein OW, Allsop JM, Mitchell A, Kaye S, Watson V, Back D, Taylor-Robinson SD, Winston A.

J Antimicrob Chemother. 2012 Jan;67(1):206-12. doi: 10.1093/jac/dkr427. Epub 2011 Oct 10.

16.

Intermittent prophylaxis with oral truvada protects macaques from rectal SHIV infection.

García-Lerma JG, Cong ME, Mitchell J, Youngpairoj AS, Zheng Q, Masciotra S, Martin A, Kuklenyik Z, Holder A, Lipscomb J, Pau CP, Barr JR, Hanson DL, Otten R, Paxton L, Folks TM, Heneine W.

Sci Transl Med. 2010 Jan 13;2(14):14ra4. doi: 10.1126/scitranslmed.3000391.

17.

Models for predicting effective HIV chemoprevention in women.

Nicol MR, Emerson CW, Prince HM, Nelson JA, Fedoriw Y, Sykes C, Geller EJ, Patterson KB, Cohen MS, Kashuba AD.

J Acquir Immune Defic Syndr. 2015 Apr 1;68(4):369-76. doi: 10.1097/QAI.0000000000000472.

PMID:
25501616
18.

Protection against rectal SHIV transmission in macaques by rectal specific-gel formulations of maraviroc and tenofovir.

Dobard CW, Taylor A, Sharma S, Anderson PL, Bushman LR, Chuong D, Pau CP, Hanson D, Wang L, Garcia-Lerma JG, McGowan I, Rohan L, Heneine W.

J Infect Dis. 2015 Jun 12. pii: jiv334. [Epub ahead of print]

PMID:
26071566
19.

CCR5 antibodies HGS004 and HGS101 preferentially inhibit drug-bound CCR5 infection and restore drug sensitivity of Maraviroc-resistant HIV-1 in primary cells.

Latinovic O, Reitz M, Le NM, Foulke JS, Fätkenheuer G, Lehmann C, Redfield RR, Heredia A.

Virology. 2011 Mar 1;411(1):32-40. doi: 10.1016/j.virol.2010.12.029. Epub 2011 Jan 12.

20.

Protection of macaques from vaginal SHIV challenge by an orally delivered CCR5 inhibitor.

Veazey RS, Springer MS, Marx PA, Dufour J, Klasse PJ, Moore JP.

Nat Med. 2005 Dec;11(12):1293-4. Epub 2005 Nov 6.

PMID:
16273102
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk